Purchase this article with an account.
M. Nazemzadeh, L. Faia, R. Shah, R. B. Nussenblatt, H. N. Sen; Daclizumab and Its Effect on Chronic Uveitic CME. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2683.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To assess the effectiveness of Daclizumab therapy in patients with cystoid macular edema related to both active and clinically quiet, non-infectious ocular inflammatory disease.
Retrospective data analysis of 37 patients with chronic intermediate or posterior uveitis with chronic CME seen and treated at the National Eye Institute, NIH between January 1997 and November 2008 were identified. Daclizumab was administered via intravenous and subcutaneous routes under four previously described protocols (NCT00043667, NCT00078689, NCT00001526, NCT00070759). Outcome measures included visual acuity, optical computed tomography (OCT), analysis of cystic lesions and retinal thickness, and fluorescein angiographic evidence of cystoid macular edema.
Among the 37 patients, diagnoses included intermediate uveitis, panuveitis, ocular sarcoidosis, Vogt-Koyanagi-Harada Disease, Behcet’s disease, retinal vasculitis, birdshot retinopathy, and ocular syphilis. Visual acuity was improved after an average of 1.6 months (range: 1-12 months) of Daclizumab therapy which usually equaled to 2 or 3 infusions/injections. Mean visual acuity improved by 6 ETRDS letters. OCT demonstrated an obvious visual diminution of cystic lesions with an average of 34 micron (range: 6-238 microns) decrease in retinal thickness. Fluorescein angiography demonstrated evidence of lessening of leakage of perifoveal capillaries compared to baseline in the majority of patients.
Clinical Trial: :
This PDF is available to Subscribers Only